BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sherman AC, Mehta A, Dickert NW, Anderson EJ, Rouphael N. The Future of Flu: A Review of the Human Challenge Model and Systems Biology for Advancement of Influenza Vaccinology. Front Cell Infect Microbiol 2019;9:107. [PMID: 31065546 DOI: 10.3389/fcimb.2019.00107] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 13.7] [Reference Citation Analysis]
Number Citing Articles
1 Riese P, Trittel S, Akmatov MK, May M, Prokein J, Illig T, Schindler C, Sawitzki B, Elfaki Y, Floess S, Huehn J, Błażejewski AJ, Strowig T, Hernandez-vargas EA, Geffers R, Zhang B, Li Y, Pessler F, Guzmán CA. Distinct immunological and molecular signatures underpinning influenza vaccine responsiveness in the elderly. Nat Commun 2022;13:6894. [DOI: 10.1038/s41467-022-34487-z] [Reference Citation Analysis]
2 Myers ML, Gallagher JR, Woolfork DD, Stradtmann-carvalho RK, Maldonado-puga S, Bock KW, Boyoglu-barnum S, Syeda H, Creanga A, Alves DA, Kanekiyo M, Harris AK. Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus. Front Immunol 2022;13:1002286. [DOI: 10.3389/fimmu.2022.1002286] [Reference Citation Analysis]
3 Ghosh A, Panda P, Halder AK, Cordeiro MNDS. In silico characterization of aryl benzoyl hydrazide derivatives as potential inhibitors of RdRp enzyme of H5N1 influenza virus. Front Pharmacol 2022;13:1004255. [DOI: 10.3389/fphar.2022.1004255] [Reference Citation Analysis]
4 Choy RKM, Bourgeois AL, Ockenhouse CF, Walker RI, Sheets RL, Flores J. Controlled Human Infection Models To Accelerate Vaccine Development. Clin Microbiol Rev. [DOI: 10.1128/cmr.00008-21] [Reference Citation Analysis]
5 Temple DS, Hegarty-Craver M, Furberg RD, Preble EA, Bergstrom E, Gardener Z, Dayananda P, Taylor L, Lemm NM, Papargyris L, McClain MT, Nicholson BP, Bowie A, Miggs M, Petzold E, Woods CW, Chiu C, Gilchrist KH. Wearable sensor-based detection of influenza in presymptomatic and asymptomatic individuals. J Infect Dis 2022:jiac262. [PMID: 35759279 DOI: 10.1093/infdis/jiac262] [Reference Citation Analysis]
6 Adams-phipps J, Toomey D, Więcek W, Schmit V, Wilkinson J, Scholl K, Jamrozik E, Osowicki J, Roestenberg M, Manheim D. A Systematic Review of Human Challenge Trials, Designs, and Safety.. [DOI: 10.1101/2022.03.20.22272658] [Reference Citation Analysis]
7 Oxford JS, Catchpole A, Mann A, Bell A, Noulin N, Gill D, Oxford JR, Gilbert A, Balasingam S. A Brief History of Human Challenge Studies (1900–2021) Emphasising the Virology, Regulatory and Ethical Requirements, Raison D’etre, Ethnography, Selection of Volunteers and Unit Design. Current Topics in Microbiology and Immunology 2022. [DOI: 10.1007/82_2022_253] [Reference Citation Analysis]
8 Thomas S, Abraham A. Progress in the Development of Structure-Based Vaccines. Vaccine Design 2022. [DOI: 10.1007/978-1-0716-1892-9_2] [Reference Citation Analysis]
9 McIlwain DR, Chen H, Rahil Z, Bidoki NH, Jiang S, Bjornson Z, Kolhatkar NS, Martinez CJ, Gaudillière B, Hedou J, Mukherjee N, Schürch CM, Trejo A, Affrime M, Bock B, Kim K, Liebowitz D, Aghaeepour N, Tucker SN, Nolan GP. Human influenza virus challenge identifies cellular correlates of protection for oral vaccination. Cell Host Microbe 2021;29:1828-1837.e5. [PMID: 34784508 DOI: 10.1016/j.chom.2021.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Becker T, Elbahesh H, Reperant LA, Rimmelzwaan GF, Osterhaus ADME. Influenza Vaccines: Successes and Continuing Challenges. J Infect Dis 2021;224:S405-19. [PMID: 34590139 DOI: 10.1093/infdis/jiab269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
11 Glud HA, George S, Skovgaard K, Larsen LE. Zoonotic and reverse zoonotic transmission of viruses between humans and pigs. APMIS 2021;129:675-93. [PMID: 34586648 DOI: 10.1111/apm.13178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Swan DA, Goyal A, Bracis C, Moore M, Krantz E, Brown E, Cardozo-Ojeda F, Reeves DB, Gao F, Gilbert PB, Corey L, Cohen MS, Janes H, Dimitrov D, Schiffer JT. Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. Viruses 2021;13:1921. [PMID: 34696352 DOI: 10.3390/v13101921] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
13 Roubidoux EK, Schultz-Cherry S. Animal Models Utilized for the Development of Influenza Virus Vaccines. Vaccines (Basel) 2021;9:787. [PMID: 34358203 DOI: 10.3390/vaccines9070787] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
14 Krüger A, de Jesus Santos AP, de Sá V, Ulrich H, Wrenger C. Aptamer Applications in Emerging Viral Diseases. Pharmaceuticals (Basel) 2021;14:622. [PMID: 34203242 DOI: 10.3390/ph14070622] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
15 Poland GA, Ovsyannikova IG, Kennedy RB. Pharmacogenomics and Vaccine Development. Clin Pharmacol Ther 2021;110:546-8. [PMID: 34097754 DOI: 10.1002/cpt.2288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Cortese M, Sherman AC, Rouphael NG, Pulendran B. Systems Biological Analysis of Immune Response to Influenza Vaccination. Cold Spring Harb Perspect Med 2021;11:a038596. [PMID: 32152245 DOI: 10.1101/cshperspect.a038596] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
17 Tomic A, Pollard AJ, Davis MM. Systems Immunology: Revealing Influenza Immunological Imprint. Viruses 2021;13:948. [PMID: 34065617 DOI: 10.3390/v13050948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Du Q, Huang W, Zhao J, Zeng J, Zhang W, Huang X, Chen R, Jiang H, Xie Y, Wang Y, Zhong N, Wang X, Yang Z. Lianhuaqingwen capsule inhibits influenza-induced bacterial adhesion to respiratory epithelial cells through down-regulation of cell adhesion molecules. J Ethnopharmacol 2021;280:114128. [PMID: 33872750 DOI: 10.1016/j.jep.2021.114128] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
19 Zhang N, Zhu L, Zhang Y, Zhou C, Song R, Yang X, Huang L, Xiong S, Huang X, Xu F, Wang Y, Wan G, Chen Z, Li A, Zhan Q, Zeng H. Circulating Rather Than Alveolar Extracellular Deoxyribonucleic Acid Levels Predict Outcomes in Influenza. J Infect Dis 2020;222:1145-54. [PMID: 32436580 DOI: 10.1093/infdis/jiaa241] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
20 McIlwain DR, Chen H, Apkarian M, Affrime M, Bock B, Kim K, Mukherjee N, Nolan GP, McNeal MM. Performance of BioFire array or QuickVue influenza A + B test versus a validation qPCR assay for detection of influenza A during a volunteer A/California/2009/H1N1 challenge study. Virol J 2021;18:45. [PMID: 33632249 DOI: 10.1186/s12985-021-01516-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Rahil Z, Leylek R, Schürch CM, Chen H, Bjornson-Hooper Z, Christensen SR, Gherardini PF, Bhate SS, Spitzer MH, Fragiadakis GK, Mukherjee N, Kim N, Jiang S, Yo J, Gaudilliere B, Affrime M, Bock B, Hensley SE, Idoyaga J, Aghaeepour N, Kim K, Nolan GP, McIlwain DR. Landscape of coordinated immune responses to H1N1 challenge in humans. J Clin Invest 2020;130:5800-16. [PMID: 33044226 DOI: 10.1172/JCI137265] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
22 Berry DA, Berry S, Hale P, Isakov L, Lo AW, Siah KW, Wong CH. A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates. PLoS One 2020;15:e0244418. [PMID: 33362278 DOI: 10.1371/journal.pone.0244418] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
23 Soldatov AA, Avdeeva ZI, Bondarev VP, Merkulov VA, Mosyagin VD, Ivanov VB, Gorenkov DV, Khantimirova LM. Russian and International Regulatory Recommendations for the Development and Marketing Authorisation of COVID-19 Vaccines in the Context of the Pandemic. Biopreparaty Profilaktika, diagnostika, lechenie 2020;20:228-244. [DOI: 10.30895/2221-996x-2020-20-4-228-244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Ganguly M, Yeolekar L, Tyagi P, Sagar U, Narale S, Anaspure Y, Tupe S, Wadkar K, Ingle N, Dhere R, Scorza FB, Mahmood K. Evaluation of manufacturing feasibility and safety of an MDCK cell-based live attenuated influenza vaccine (LAIV) platform. Vaccine 2020;38:8379-86. [PMID: 33229107 DOI: 10.1016/j.vaccine.2020.10.092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Jamrozik E, Littler K, Bull S, Emerson C, Kang G, Kapulu M, Rey E, Saenz C, Shah S, Smith PG, Upshur R, Weijer C, Selgelid MJ; WHO Working Group for Guidance on Human Challenge Studies in COVID-19. Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group. Vaccine 2021;39:633-40. [PMID: 33341309 DOI: 10.1016/j.vaccine.2020.10.075] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
26 Innis BL, Scorza FB, Blum JS, Jain VK, Aguilar AO, Post DJ, Roberts PC, Wairagkar N, White J, Bresee J. Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations. Vaccine 2019;37:4830-4. [PMID: 31362820 DOI: 10.1016/j.vaccine.2019.06.053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
27 Innis BL, Berlanda Scorza F, Blum JS, Jain VK, Older Aguilar A, Post DJ, Roberts PC, Wairagkar N, White J, Bresee J. Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity. Vaccine 2019;37:4823-9. [PMID: 31362819 DOI: 10.1016/j.vaccine.2019.06.080] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
28 Spinola SM, Zimet GD, Ott MA, Katz BP. Human Challenge Studies Are Unlikely to Accelerate Coronavirus Vaccine Licensure Due to Ethical and Practical Issues. J Infect Dis 2020;222:1572-4. [PMID: 32845303 DOI: 10.1093/infdis/jiaa457] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
29 Berry DA, Berry S, Hale P, Isakov L, Lo AW, Siah KW, Wong CH. A Cost/Benefit Analysis of Clinical Trial Designs for COVID-19 Vaccine Candidates.. [DOI: 10.1101/2020.09.15.20195495] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Trovato M, Sartorius R, D'Apice L, Manco R, De Berardinis P. Viral Emerging Diseases: Challenges in Developing Vaccination Strategies. Front Immunol 2020;11:2130. [PMID: 33013898 DOI: 10.3389/fimmu.2020.02130] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 21.0] [Reference Citation Analysis]
31 Noé A, Cargill TN, Nielsen CM, Russell AJC, Barnes E. The Application of Single-Cell RNA Sequencing in Vaccinology. J Immunol Res 2020;2020:8624963. [PMID: 32802896 DOI: 10.1155/2020/8624963] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
32 Pagadala NS, Bhat R, Kumar D J, Landi A. Discovery of anti-influenza nucleoside triphosphates targeting the catalytic site of A/PR/8/34/H1N1 polymerase. Med Chem Res 2020;29:1463-1477. [DOI: 10.1007/s00044-020-02561-0] [Reference Citation Analysis]
33 Tambornino L, Lanzerath D. COVID-19 human challenge trials – what research ethics committees need to consider. Research Ethics 2020;16:1-11. [DOI: 10.1177/1747016120943635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Mammas IN, Drysdale SB, Rath B, Theodoridou M, Papaioannou G, Papatheodoropoulou A, Koutsounaki E, Koutsaftiki C, Kozanidou E, Achtsidis V, Korovessi P, Chrousos GP, Spandidos DA. Update on current views and advances on RSV infection (Review). Int J Mol Med 2020;46:509-20. [PMID: 32626981 DOI: 10.3892/ijmm.2020.4641] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
35 Eyal N, Lipsitch M, Smith PG. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. J Infect Dis 2020;221:1752-6. [PMID: 32232474 DOI: 10.1093/infdis/jiaa152] [Cited by in Crossref: 146] [Cited by in F6Publishing: 154] [Article Influence: 73.0] [Reference Citation Analysis]
36 Pawelec G, McElhaney J. Recent advances in influenza vaccines. F1000Res 2020;9:F1000 Faculty Rev-305. [PMID: 32399192 DOI: 10.12688/f1000research.22611.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
37 Plotkin SA, Caplan A. Extraordinary diseases require extraordinary solutions. Vaccine 2020;38:3987-8. [PMID: 32331807 DOI: 10.1016/j.vaccine.2020.04.039] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 26.5] [Reference Citation Analysis]
38 Saxena SK, Maurya VK, Kumar S, Bhatt MLB. Pandemic Influenza A Virus (pH1N1). Livestock Diseases and Management 2020. [DOI: 10.1007/978-981-15-2651-0_6] [Reference Citation Analysis]
39 Sunita, Sajid A, Singh Y, Shukla P. Computational tools for modern vaccine development. Hum Vaccin Immunother 2020;16:723-35. [PMID: 31545127 DOI: 10.1080/21645515.2019.1670035] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
40 Dugan HL, Henry C, Wilson PC. Aging and influenza vaccine-induced immunity. Cell Immunol 2020;348:103998. [PMID: 31733824 DOI: 10.1016/j.cellimm.2019.103998] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 18.3] [Reference Citation Analysis]
41 Xiao Y, Park JK, Williams S, Ramuta M, Cervantes-Medina A, Bristol T, Smith S, Czajkowski L, Han A, Kash JC, Memoli MJ, Taubenberger JK. Deep sequencing of 2009 influenza A/H1N1 virus isolated from volunteer human challenge study participants and natural infections. Virology 2019;534:96-107. [PMID: 31226666 DOI: 10.1016/j.virol.2019.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]